AROC — AroCell AB (publ) Share Price
Last trade - 00:00- SEK133.61m
- SEK85.82m
- SEK57.44m
- 47
- 25
- 51
- 31
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.1 | ||
| Price to Tang. Book | 2.39 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.33 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -35.83% | ||
| Return on Equity | -29.81% | ||
| Operating Margin | -75.61% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 0.08 | 12 | 36.99 | 43.04 | 57.44 | 70 | 90 | 164.62% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AroCell AB (publ) is a Sweden-based diagnostic Company engaged in the development of markers for determination of cell growth (TK 210) and apoptosis. The Company's principal product candidate, TK-immuno/hem, is a test for monitoring and follow up of blood cancer. The test is based on a patented technology, which have already been evaluated in an early product prototype ELISA method. Apart from that, the Company develops a marker for solid tumor cancer disease. The AroCell cooperates with partners within development, production and sales.
Directors
- Claes Post CHM (69)
- Anders Hultman CEO (47)
- Martin Shaw VBD
- Kiran Jagarlamudi OTH
- Peter Lowendahl OTH
- Alf Malmberg OTH
- Helena Wensman OTH
- Staffan Eriksson DRC
- Karin Eriksson-Vidblom DRC
- Agneta Franksson DRC (55)
- Gunnar Steineck DRC
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 29th, 2000
- Public Since
- May 25th, 2011
- No. of Employees
- 22
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 230,361,066
- Address
- Karlsbodavagen 39, BROMMA, 168 67
- Web
- https://arocell.com/
- Phone
- +46 87996750
- Contact
- Anders Hultman
- Auditors
- Ohrlings PricewaterhouseCoopers AB
Upcoming Events for AROC
Similar to AROC
2cureX AB
OMX Nordic Exchange Stockholm
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
Alligator Bioscience AB
OMX Nordic Exchange Stockholm
AlzeCure Pharma AB
OMX Nordic Exchange Stockholm
FAQ
As of Today at 19:20 UTC, shares in AroCell AB (publ) are trading at SEK0.58. This share price information is delayed by 15 minutes.
Shares in AroCell AB (publ) last closed at SEK0.58 and the price had moved by +56.76% over the past 365 days. In terms of relative price strength the AroCell AB (publ) share price has outperformed the FTSE Global All Cap Index by +52.83% over the past year.
There is no consensus recommendation for this security.
Find out moreAroCell AB (publ) does not currently pay a dividend.
AroCell AB (publ) does not currently pay a dividend.
AroCell AB (publ) does not currently pay a dividend.
To buy shares in AroCell AB (publ) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK0.58, shares in AroCell AB (publ) had a market capitalisation of SEK133.61m.
Here are the trading details for AroCell AB (publ):
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: AROC
Based on an overall assessment of its quality, value and momentum AroCell AB (publ) is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in AroCell AB (publ) is SEK0.90. That is 55.17% above the last closing price of SEK0.58.
Analysts covering AroCell AB (publ) currently have a consensus Earnings Per Share (EPS) forecast of -SEK0.20 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AroCell AB (publ). Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +15.85%.
As of the last closing price of SEK0.58, shares in AroCell AB (publ) were trading +13.37% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The AroCell AB (publ) PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK0.58.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
AroCell AB (publ)'s management team is headed by:
- Claes Post - CHM
- Anders Hultman - CEO
- Martin Shaw - VBD
- Kiran Jagarlamudi - OTH
- Peter Lowendahl - OTH
- Alf Malmberg - OTH
- Helena Wensman - OTH
- Staffan Eriksson - DRC
- Karin Eriksson-Vidblom - DRC
- Agneta Franksson - DRC
- Gunnar Steineck - DRC